Refine
Year of publication
- 2017 (3) (remove)
Document Type
- Article (1)
- Conference Proceeding (1)
- Preprint (1)
Language
- English (3)
Has Fulltext
- yes (3)
Is part of the Bibliography
- no (3)
Keywords
- anatomy ontologies (1)
- bevacizumab (1)
- elderly (1)
- first-line chemotherapy (1)
- literature digitization (1)
- metastatic colorectal cancer (1)
- non-commercial publishing (1)
- open access (1)
- text mining tools (1)
Institute
The ALICE experiment has measured the inclusive J/ψ production in Pb-Pb collisions at sNN−−−√=2.76 TeV down to zero transverse momentum in the rapidity range 2.5<y<4. A suppression of the inclusive J/ψ yield in Pb-Pb is observed with respect to the one measured in pp collisions scaled by the number of binary nucleon-nucleon collisions. The nuclear modification factor, integrated over the 0-80% most central collisions, is 0.545±0.032(stat.)±0.083(syst.) and does not exhibit a significant dependence on the collision centrality. These features appear significantly different from measurements at lower collision energies. Models including J/ψ production from charm quarks in a deconfined partonic phase can describe our data.
In order to promote the accessibility of biodiversity data in historic and contemporary literature, we introduce a new interdisciplinary project called BIOfid (FID=Fachinformationsdienst, a service for providing specialized information). The project aims at a mobilization of data available in print only by combining digitization of scientific biodiversity literature with the development of innovative text mining tools for complex, eventually semantic searches throughout the complete text corpus. A major prerequisite for the development of such search tools is the provision of sophisticated anatomy ontologies on the one hand, and of complete lists of species names (currently considered valid as well as all synonyms) at a global scale on the other hand. In the initial stage, we chose examples from German publications of the past 250 years dealing with the geographic distribution and ecology of vascular plants (Tracheophyta), birds (Aves), as well as moths and butterflies (Lepidoptera) in Germany. These taxa have been prioritized according to current demands of German research groups (about 50 sites) aiming at analyses and modeling of distribution patterns and their changes through time. In the long term, we aim at providing data and open source software applicable for any taxon and geographic region. For this purpose, a platform for open access journals for long-term availability of professional e-journals will be established. All generated data will also be made accessible through GFBio (German Federation for Biological Data). BIOfid is supported by the LIS-Scientific Library Services and Information Systems program of the German Research Foundation (DFG).
Background: The aim of this meta-analysis was to evaluate efficacy and safety of first-line chemotherapy with or without a monoclonal antibody in elderly patients ( ≥ 70 years) with metastatic colorectal cancer (mCRC), since they are frequently underrepresented in clinical trials.
Results: Individual data from 10 studies were included. From a total of 3271 patients, 604 patients (18%) were ≥ 70 years (median 73 years, range 70–88). Of these, 335 patients were treated with a bevacizumab-based first-line regimen and 265 were treated with chemotherapy only. The median PFS was 8.2 vs. 6.5 months and the median OS was 16.7 vs. 13.0 months in patients treated with and without bevacizumab, respectively. The safety profile of bevacizumab in combination with first-line chemotherapy did not differ from published clinical trials.
Materials and Methods: PubMed and Cochrane Library searches were performed on 29 April 2013 and studies published to this date were included. Authors were contacted to request progression-free survival (PFS), overall survival (OS) data, patient data on treatment regimens, age, sex and potential signs of toxicity in patients ≥ 70 years of age.
Conclusions: This meta-analysis suggests that the addition of bevacizumab to standard first-line chemotherapy improves clinical outcome in elderly patients with mCRC and is well tolerated.